Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
A phase 1 trial of JS001, a monoclonal antibody targeting programmed death-1 (PD-1) in patients with advanced or recurrent malignancies. This is an ASCO Meeting Abstract from the 2017 ASCO Annual ...
Researchers at MD Anderson have identified RNase H2 as a key survival mechanism in triple-negative breast cancer, helping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results